Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-κB signaling

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2115-2125

  Yin, Qian Qian ^a   Liu, Chuan Xu ^a   Wu, Ying Li ^a   Wu, Shao Fang ^a   Wang, Yan ^a   Zhang, Xia ^a   Hu, Xiao Juan ^a   Pu, Jian Xin ^b   Lu, Ying ^a   Zhou, Hu Chen ^a   Wang, Hong Lin ^a   Nie, Hong ^a   Sun, Han Dong ^b   Chen, Guo Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENANTHIN; DITERPENOID; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PLACEBO; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DRUG TARGETING; IMMUNOMODULATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; DITERPENES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84883439176     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203546     Document Type: Article

References (50)

1. Nylander, A., and D. A. Hafler. 2012. Multiple sclerosis. J. Clin. Invest. 122: 1180-1188.
2. Sellner, J., J. Kraus, A. Awad, R. Milo, B. Hemmer, and O. Stüve. 2011. The increasing incidence and prevalence of female multiple sclerosis: a critical analysis of potential environmental factors. Autoimmun. Rev. 10: 495-502.
3. Steinman, L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2: 762-764.
4. Yan, J., and J. M. Greer. 2008. NF-κB, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 7: 536-557.
5. Mattson, M. P., and S. Camandola. 2001. NF-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107: 247-254.
6. Tak, P. P., and G. S. Firestein. 2001. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 107: 7-11.
7. Lassmann, H. 2008. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr. Opin. Neurol. 21: 242-247.
8. Matsushita, T. 2011. [Multiple sclerosis: current therapies and future perspectives]. Nippon Rinsho 69: 2077-2086.
9. Gawronski, K. M., M. M. Rainka, M. J. Patel, and F. M. Gengo. 2010. Treatment options for multiple sclerosis: current and emerging therapies. Pharmacotherapy 30: 916-927.
10. Perumal, J., and O. Khan. 2012. Emerging disease-modifying therapies in multiple sclerosis. Curr. Treat. Options Neurol. 14: 256-263.
11. Sun, H. D., S. X. Huang, and Q. B. Han. 2006. Diterpenoids from Isodon species and their biological activities. Nat. Prod. Rep. 23: 673-698.
12. Jiang, B., H. Yang, M. L. Li, A. J. Hou, Q. B. Han, S. J. Wang, S. H. Li, and H. D. Sun. 2002. Diterpenoids from Isodon adenantha. J. Nat. Prod. 65: 1111-1116.
13. Hanson, J. R. 2009. Diterpenoids. Nat. Prod. Rep. 26: 1156-1171.
14. Roberts, S. C. 2007. Production and engineering of terpenoids in plant cell culture. Nat. Chem. Biol. 3: 387-395.
15. Liu, C. X., Q. Q. Yin, H. C. Zhou, Y. L. Wu, J. X. Pu, L. Xia, W. Liu, X. Huang, T. Jiang, M. X. Wu, et al. 2012. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat. Chem. Biol. 8: 486-493.
16. Blackwell, T. S., F. E. Yull, C. L. Chen, A. Venkatakrishnan, T. R. Blackwell, D. J. Hicks, L. H. Lancaster, J. W. Christman, and L. D. Kerr. 2000. Multiorgan nuclear factor κB activation in a transgenic mouse model of systemic inflammation. Am. J. Respir. Crit. Care Med. 162: 1095-1101.
17. Aizman, E., A. Mor, J. Chapman, Y. Assaf, and Y. Kloog. 2010. The combined treatment of copaxone and salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. J. Neuroimmunol. 229: 192-203.
18. Weber, M. S., T. Prod'homme, S. Youssef, S. E. Dunn, C. D. Rundle, L. Lee, J. C. Patarroyo, O. Stüve, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13: 935-943.
19. Racke, M. K., and A. E. Lovett-Racke. 2011. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J. Immunol. 186: 1887-1890.
20. Aharoni, R. 2013. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun. Rev. 12: 543-553.
21. Ziemssen, T., and F. Ziemssen. 2005. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 4: 460-467.
22. Hafler, D. A. 2004. Multiple sclerosis. J. Clin. Invest. 113: 788-794.
23. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
24. Cavone, L., and A. Chiarugi. 2012. Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis? Trends Mol. Med. 18: 92-100.
25. Wan, B., H. Nie, A. Liu, G. Feng, D. He, R. Xu, Q. Zhang, C. Dong, and J. Z. Zhang. 2006. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177: 8844-8850.
26. Zozulya, A. L., B. D. Clarkson, S. Ortler, Z. Fabry, and H. Wiendl. 2010. The role of dendritic cells in CNS autoimmunity. J. Mol. Med. 88: 535-544.
27. Bauer, J., I. Huitinga, W. Zhao, H. Lassmann, W. F. Hickey, and C. D. Dijkstra. 1995. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 15: 437-446.
28. Gutcher, I., and B. Becher. 2007. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 117: 1119-1127.
29. Gerondakis, S., and U. Siebenlist. 2010. Roles of the NF-κB pathway in lymphocyte development and function. Cold Spring Harb. Perspect. Biol. 2: a000182.
30. Brown, K. D., E. Claudio, and U. Siebenlist. 2008. The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res. Ther. 10: 212.
31. Stoffel, A. 2005. The NF-κB signalling pathway: a therapeutic target in lymphoid malignancies? Expert Opin. Ther. Targets 9: 1045-1061.
32. Au, R. Y., A. E. Jedlicka, W. Li, A. Pekosz, and S. L. Klein. 2010. Seoul virus suppresses NF-κB-mediated inflammatory responses of antigen presenting cells from Norway rats. Virology 400: 115-127.
33. van de Laar, L., A. van den Bosch, S. W. van der Kooij, H. L. Janssen, P. J. Coffer, C. van Kooten, and A. M. Woltman. 2010. A nonredundant role for canonical NF-κB in human myeloid dendritic cell development and function. J. Immunol. 185: 7252-7261.
34. Hilliard, B., E. B. Samoilova, T. S. Liu, A. Rostami, and Y. Chen. 1999. Experimental autoimmune encephalomyelitis in NF-κB-deficient mice:roles of NFκB in the activation and differentiation of autoreactive T cells. J. Immunol. 163: 2937-2943.
35. Pahan, K., and M. Schmid. 2000. Activation of nuclear factor-κB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 287: 17-20.
36. van Loo, G., R. De Lorenzi, H. Schmidt, M. Huth, A. Mildner, M. Schmidt-Supprian, H. Lassmann, M. R. Prinz, and M. Pasparakis. 2006. Inhibition of transcription factor NF-κB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 7: 954-961.
37. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109 (Suppl): S81-S96.
38. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18: 621-663.
39. Liu, C. X., H. C. Zhou, Q. Q. Yin, Y. L. Wu, and G. Q. Chen. 2013. Targeting peroxiredoxins against leukemia. Exp. Cell Res. 319: 170-176.
40. Wang, W., S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang. 2012. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol. Int. 32: 887-893.
41. Bluestone, J. A. 2005. Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5: 343-349.
42. H-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8: 345-350.
43. Almolda, B., B. Gonzalez, and B. Castellano. 2011. Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front. Biosci. 16: 1157-1171.
44. Ishii, T., E. Warabi, and T. Yanagawa. 2012. Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. J. Clin. Biochem. Nutr. 50: 91-105.
45. Riddell, J. R., X. Y. Wang, H. Minderman, and S. O. Gollnick. 2010. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J. Immunol. 184: 1022-1030.
46. Miller, S. C., R. Huang, S. Sakamuru, S. J. Shukla, M. S. Attene-Ramos, P. Shinn, D. Van Leer, W. Leister, C. P. Austin, and M. Xia. 2010. Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem. Pharmacol. 79: 1272-1280.
47. Gupta, S. C., C. Sundaram, S. Reuter, and B. B. Aggarwal. 2010. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta 1799: 775-787.
48. Greve, B., R. Weissert, N. Hamdi, E. Bettelli, R. A. Sobel, A. Coyle, V. K. Kuchroo, K. Rajewsky, and M. Schmidt-Supprian. 2007. IκB kinase 2/β deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 179: 179-185.
49. Neurath, M. F., S. Pettersson, K. H. Meyer zum Büschenfelde, and W. Strober. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 2: 998-1004.
50. Aupperle, K., B. Bennett, Z. Han, D. Boyle, A. Manning, and G. Firestein. 2001. NF-κB regulation by IκB kinase-2 in rheumatoid arthritis synoviocytes. J. Immunol. 166: 2705-2711.